Literature DB >> 2843775

Lymphocyte activation by HIV-1 envelope glycoprotein.

H Kornfeld1, W W Cruikshank, S W Pyle, J S Berman, D M Center.   

Abstract

Cell activation by phytohaemagglutinin, phorbol ester and by the supernatant of phytohaemagglutinin-stimulated peripheral blood mononuclear cells induces the expression and cytopathic effects of latent human immunodeficiency virus type-1 (HIV-1) in vitro. The lymphocyte surface protein CD4 has been identified as a receptor for HIV-1 and binds the viral envelope glycoprotein (gp120). In the light of evidence indicating that one natural function of CD4 is as a growth factor receptor, we examined the ability of native gp120 to activate resting CD4-bearing lymphocytes. Our results indicate that gp120 has innate biological activity as a result of a specific interaction with CD4, inducing increases in intracellular levels of inositol trisphosphate and of calcium, and in interleukin-2 receptor expression and cell motility.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2843775     DOI: 10.1038/335445a0

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  52 in total

1.  Inhibition of HIV-1-mediated syncytium formation and virus replication by the lipophosphoglycan from Leishmania donovani is due to an effect on early events in the virus life cycle.

Authors:  N Genois; B Barbeau; M Olivier; M J Tremblay
Journal:  Clin Exp Immunol       Date:  2001-04       Impact factor: 4.330

2.  HIV envelope induces a cascade of cell signals in non-proliferating target cells that favor virus replication.

Authors:  Claudia Cicala; James Arthos; Sara M Selig; Glynn Dennis; Douglas A Hosack; Donald Van Ryk; Marion L Spangler; Tavis D Steenbeke; Prateeti Khazanie; Neil Gupta; Jun Yang; Marybeth Daucher; Richard A Lempicki; Anthony S Fauci
Journal:  Proc Natl Acad Sci U S A       Date:  2002-06-27       Impact factor: 11.205

3.  A gp120 HIV peptide with high similarity to HLA class II beta chains enhances PPD-specific and autoreactive T cell activation.

Authors:  O Pugliese; M Viora; B Camponeschi; P Cordiali Fei; F Caprilli; A Chersi; M Evangelista; A M Di Massimo; V Colizzi
Journal:  Clin Exp Immunol       Date:  1992-11       Impact factor: 4.330

4.  Apoptosis as a mechanism of cell death in cultured T lymphoblasts acutely infected with HIV-1.

Authors:  C Terai; R S Kornbluth; C D Pauza; D D Richman; D A Carson
Journal:  J Clin Invest       Date:  1991-05       Impact factor: 14.808

5.  The cytoplasmic tail of CD4 is required for inhibition of human immunodeficiency virus type 1 replication by antibodies that bind to the immunoglobulin CDR3-like region in domain 1 of CD4.

Authors:  M Benkirane; H Schmid-Antomarchi; D R Littman; M Hirn; B Rossi; C Devaux
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

6.  Pentosan polysulfate, a potent anti HIV and anti tumor agent, inhibits protein serine/threonine and tyrosine kinases.

Authors:  A K Srivastava; R P Sékaly; J L Chiasson
Journal:  Mol Cell Biochem       Date:  1993-03-24       Impact factor: 3.396

7.  Human immunodeficiency virus proteins induce the inhibitory cAMP/protein kinase A pathway in normal lymphocytes.

Authors:  B Hofmann; P Nishanian; T Nguyen; P Insixiengmay; J L Fahey
Journal:  Proc Natl Acad Sci U S A       Date:  1993-07-15       Impact factor: 11.205

Review 8.  The human immunodeficiency virus type 1 (HIV-1) CD4 receptor and its central role in promotion of HIV-1 infection.

Authors:  S Bour; R Geleziunas; M A Wainberg
Journal:  Microbiol Rev       Date:  1995-03

9.  Human immunodeficiency virus type 1 gp120 reprogramming of CD4+ T-cell migration provides a mechanism for lymphadenopathy.

Authors:  Daniel S Green; David M Center; William W Cruikshank
Journal:  J Virol       Date:  2009-03-18       Impact factor: 5.103

10.  Repression of human immunodeficiency virus type 1 long terminal repeat-driven gene expression by binding of the virus to its primary cellular receptor, the CD4 molecule.

Authors:  P Bérubé; B Barbeau; R Cantin; R P Sékaly; M Tremblay
Journal:  J Virol       Date:  1996-06       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.